Patent expiry and costs for anti-cancer medicines for clinical use: expiry and costs anti-cancer medicines

Research output: Research - peer-reviewEditorial

Drs Brian Godman, Claudia Wild and Alan Haycox review the paper by Venkatesan et al on the patent expiry of (non-) tyrosine kinase inhibitors.
Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalGenerics and Biosimilars Initiative journal
StateAccepted/In press - 17 Mar 2017

    Research areas

  • anti cancer medicines, medicine patents, tyrosine kinase inhibitors

View graph of relations